Testagen: a reproductive-health claim with only early laboratory evidence

## What is it? Testagen is the short peptide Lys-Glu-Asp-Gly (KEDG), often described as a testicular or reproductive-system bioregulator. That proposed target is a marketing or mechanistic hypothesis, not a demonstrated clinical benefit. [1]

## What do studies show? In a laboratory study, fluorescently labeled Testagen and other short peptides entered HeLa cells, and the peptides interacted with DNA-related materials in vitro. The study did not administer Testagen to patients or measure testosterone, sperm quality, fertility, symptoms, or long-term safety. Cell entry and DNA binding do not show that a vial improves reproductive health. [1]

## Safety For an unapproved research peptide, whole-body safety, purity, interactions, and effects on fertility are uncertain. Persistent low testosterone or infertility has multiple possible causes and warrants a medical evaluation rather than an assumption about this peptide. [1]

## How much? The published cell experiment offers no adult dosing schedule. No safe and effective human Testagen dose, or independently verifiable exact-product anecdotal dose, was identified. A quantity printed on a vial is its contents, not a studied dose. [1]